CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 13,945 enrolled
Drug / intervention
apixaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05795062
NCT05795062N/ACompleted
CompareCT.gov

Post-Discharge Treatment Patterns and Outcomes in Patients With Venous Thromboembolism

Pfizer·observational·Posted Apr 3, 2023·Updated Nov 22, 2024

In Brief

An observational study evaluating apixaban and warfarin for Venous Thromboembolism. Completed, enrolled 13,945 participants across 1 site.

Detailed Summary

The purpose of this study is to assess outpatient treatment patterns following hospitalization for venous thromboembolism (VTE). VTE is a condition that occurs when blood clot forms in the vein. This is a retrospective study (assessments on events that have already occurred) of healthcare claims from databases. The study sponsors will assess healthcare claim records of patients treated with either apixaban or warfarin. Assessment includes treatment persistence, switch, and stopping therapy, along with recurrent VTE and bleeding.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thromboembolism
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

N/ACompletedFinished
202420252026
First PostedApr 3, 2023
Enrollment StartMar 10, 2023
Primary CompletionSep 30, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.2 years ago

Interventions

apixabandrug

patients treated with apixaban

warfarindrug

patients treated with warfarin